Autologous Stem Cell Rescue for Primary Amyloidosis

Not Recruiting

Trial ID: NCT00186407

Purpose

To evaluate the role of high dose therapy and autologous hematopoietic cell transplant for amyloidosis.

Official Title

High Dose Chemotherapy and Autologous Stem Cell Rescue for Primary Amyloidosis

Stanford Investigator(s)

Sally Arai
Sally Arai

Associate Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)

Robert Lowsky
Robert Lowsky

Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)

Laura Johnston
Laura Johnston

Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)

Robert Negrin
Robert Negrin

Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)

Eligibility


Inclusion Criteria:1. Primary amyloidosis

2. Age < 75 years.

3. Patients must have their pathology reviewed and the diagnosis confirmed at Stanford
University Medical Center.

4. Patients who have undergone bone marrow transplantation previously will not be eligible.

5. Patients must have a Karnofsky performance status greater than 70%.

6. Patients must have a serum creatinine less than 2 mg/dl or creatinine clearance greater
than 30 ml/min, bilirubin less than 2 mg/dl, transaminases less than two times normal, left
ventricular ejection fraction >45% on echocardiography, cardiac index > 1.8 liters/min/m^2
and pulmonary function tests demonstrating FEV1 and DLCO > 60%.

7. Patients must be HIV negative.

8. Pregnant or lactating women will not be eligible to participate.

9. Patients must provide signed informed consent.

10. Patients with multiple myeloma and amyloid are eligible.

Exclusion Criteria:1. prior blood or marrow transplant

Intervention(s):

procedure: high dose chemo then auto hematopoietic cell transplant

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
BMT Referrals
6507230822

New Trial Alerts